Most Shorted Stocks
GH is part of our most shorted stocks screen list, indicating it has a high short interest.
GUARDANT HEALTH INC (GH) Stock Price & Overview
NASDAQ:GH • US40131M1099
Current stock price
83.24 USD
-5.26 (-5.94%)
Last:
The current stock price of GH is 83.24 USD. Today GH is down by -5.94%. In the past month the price increased by 4.6%. In the past year, price increased by 88.9%.
GH Key Statistics
52-Week Range36.36 - 120.74
Current GH stock price positioned within its 52-week range.
1-Month Range74.55 - 99
Current GH stock price positioned within its 1-month range.
- Market Cap
- 10.919B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.36
- Dividend Yield
- N/A
GH Stock Performance
Today
-5.94%
1 Week
-2.82%
1 Month
+4.60%
3 Months
-22.40%
Longer-term
6 Months -4.86%
1 Year +88.90%
2 Years +391.67%
3 Years +292.29%
5 Years -44.33%
10 Years N/A
GH Stock Chart
GH Stock Screens
GH currently appears in the following ChartMill screener lists.
GH Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GH. When comparing the yearly performance of all stocks, GH is one of the better performing stocks in the market, outperforming 85.42% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
GH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GH. The financial health of GH is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GH Earnings
On February 19, 2026 GH reported an EPS of -1 and a revenue of 281.27M. The company missed EPS expectations (-38.56% surprise) and beat revenue expectations (0.76% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-$1.00
Revenue Reported281.266M
EPS Surprise -38.56%
Revenue Surprise 0.76%
GH Forecast & Estimates
34 analysts have analysed GH and the average price target is 132.26 USD. This implies a price increase of 58.9% is expected in the next year compared to the current price of 83.24.
For the next year, analysts expect an EPS growth of 13.91% and a revenue growth 30.9% for GH
Analysts
Analysts85.88
Price Target132.26 (58.89%)
EPS Next Y13.91%
Revenue Next Year30.9%
GH Groups
Sector & Classification
GH Financial Highlights
Over the last trailing twelve months GH reported a non-GAAP Earnings per Share(EPS) of -3.36. The EPS increased by 5.62% compared to the year before.
Income Statements
Revenue(TTM)982.02M
Net Income(TTM)-416.28M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-11.11%
Sales Q2Q%39.37%
EPS 1Y (TTM)5.62%
Revenue 1Y (TTM)32.88%
GH Ownership
Ownership
Inst Owners101.2%
Shares131.17M
Float125.68M
Ins Owners4.04%
Short Float %9.26%
Short Ratio5.81
GH Competitors/Peers
The largest stocks on the US markets in the "Health Care Services" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.2 | 100.426B | ||
| CI | THE CIGNA GROUP | 9.2 | 74.505B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 99.67 | 31.083B | ||
| DGX | QUEST DIAGNOSTICS INC | 17.01 | 21.763B | ||
| LH | LABCORP HOLDINGS INC | 14.32 | 21.651B | ||
| DVA | DAVITA INC | 10.73 | 10.023B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 30.05 | 9.382B | ||
| HIMS | HIMS & HERS HEALTH INC | 48.16 | 6.699B | ||
| CHE | CHEMED CORP | 15.93 | 6.176B | ||
| RDNT | RADNET INC | 86.6 | 4.482B | ||
| OPCH | OPTION CARE HEALTH INC | 14.68 | 4.385B | ||
| BLLN | BILLIONTOONE INC CL A | 157.35 | 3.759B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GH
Company Profile
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Company Info
IPO: 2018-10-04
GUARDANT HEALTH INC
3100 Hanover Street
Palo Alto CALIFORNIA 94063 US
CEO: Helmy Eltoukhy
Employees: 2498
Phone: 18556988887
GUARDANT HEALTH INC / GH FAQ
What does GUARDANT HEALTH INC do?
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Can you provide the latest stock price for GUARDANT HEALTH INC?
The current stock price of GH is 83.24 USD. The price decreased by -5.94% in the last trading session.
What is the dividend status of GUARDANT HEALTH INC?
GH does not pay a dividend.
How is the ChartMill rating for GUARDANT HEALTH INC?
GH has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about GUARDANT HEALTH INC (GH) stock?
34 analysts have analysed GH and the average price target is 132.26 USD. This implies a price increase of 58.9% is expected in the next year compared to the current price of 83.24.
What is GUARDANT HEALTH INC worth?
GUARDANT HEALTH INC (GH) has a market capitalization of 10.92B USD. This makes GH a Large Cap stock.
What is the Short Interest ratio of GUARDANT HEALTH INC (GH) stock?
The outstanding short interest for GUARDANT HEALTH INC (GH) is 9.26% of its float.